Stockscreener 앱 받기
16.38
2.44%
0.39
시간 외 거래:
16.38
전일 마감가:
$15.99
열려 있는:
$16.21
하루 거래량:
4.00M
Relative Volume:
1.76
시가총액:
$1.40B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-5.5338
EPS:
-2.96
순현금흐름:
$-160.60M
1주 성능:
+9.79%
1개월 성능:
+19.82%
6개월 성능:
-19.39%
1년 성능:
-26.32%
1일 변동 폭
$16.12
$16.95
1주일 범위
$14.53
$16.95
52주 변동 폭
$12.06
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
35 GATEHOUSE DRIVE, WALTHAM, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.38 | 1.40B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.7%Here's What Happened - MarketBeat
Should investors be concerned about SNDX’s high price-to-sales ratio? - US Post News
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday - MarketBeat
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
When (SNDX) Moves Investors should Listen - Stock Traders Daily
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth with FDA approvals - Investing.com
Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Sells 4,618 Shares of Stock - MarketBeat
Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of Stock - MarketBeat
Michael A. Metzger Sells 13,288 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Syndax pharmaceuticals CFO Keith Goldan sells $58,558 in stock - MSN
Don't Ignore The Insider Selling In Syndax Pharmaceuticals - Simply Wall St
abrdn plc Takes Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax pharmaceuticals CFO sells $58,558 in stock - MSN
Syndax Pharmaceuticals CEO sells $206,017 in shares - MSN
Syndax pharmaceuticals CFO Keith Goldan sells $58,558 in stock By Investing.com - Investing.com Australia
Syndax pharmaceuticals CFO sells $58,558 in stock By Investing.com - Investing.com Nigeria
Syndax Pharmaceuticals CEO sells $206,017 in shares By Investing.com - Investing.com South Africa
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc (SNDX) positioned for future growth? - SETE News
2 ‘Strong Buy’ Growth Stocks Poised For 141% To 193% Gains, According To Wall Street - Barchart
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap UpShould You Buy? - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Learn to Evaluate (SNDX) using the Charts - Stock Traders Daily
Syndax Pharmaceuticals Inc [SNDX] stock for 25,037 USD was acquired by Goldan Keith A. - Knox Daily
Syndax Pharmaceuticals Inc (SNDX) deserves deeper analysis - US Post News
Kura Oncology falls despite trial success; rival Syndax gains - Seeking Alpha
Can Syndax Pharmaceuticals Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Syndax Expands Team: Strategic Stock Options Grant Signals Major Growth Phase - StockTitan
Ready to Jump After Recent Trade: Syndax Pharmaceuticals Inc (SNDX) - SETE News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Syndax Leadership Reveals Growth Strategy at Elite Healthcare Investment Forums - StockTitan
Syndax Announces Participation in February Investor Conferences - Yahoo Finance
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Incyte and Syndax to scale Niktimvo production after FDA approval - BioProcess Insider
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):